

Catalog# BP- 50572

Daclizumab Biosimilar (CD25 Monoclonal Antibody)

Daclizumab Biosimilar uses the same protein sequences as the therapeutic antibody daclizumab.

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.

Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Product Details	
CAS No.	152923-56-3
Species Reactivity	Human
Source	Daclizumab biosimilar CHO stable cell line
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Daclizumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human interleukin-2 receptor (anti-Tac or anti-CD25)
Purity	>95%
Molecular Weight	144.24 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 μ M filtered solution, pH 6.0
Storage conditions	4°C for short time, -20°C or -80°C for long time.